FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.
H. Lundbeck A/S announced results from FOCUS, a new study showing that Brintellix (vortioxetine) 10 mg and 20 mg, met...
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that often persists throughout life. Approximately two-thirds of patients with a childhood diagnosis of ADHD continue to experience clinically significant...
Watch our short and informative videos featuring experts Professor Robert Storey and Dr Marc P Bonaca.
EQRx resets to focus on clinically differentiated medicines: Prioritizing development of lerociclib (CDK 4/6 inhibitor); initiated Phase III trial in first-line advanced endometrial cancer; enrollment in Phase II trial in first- and second-line advanced breast cancer near completion, providing a foundation for future combination development opportunities.
Mateon Therapeutics, Inc. announced results from its third scheduled interim analysis of the phase II/III FOCUS study evaluating CA4P (fosbretabulin)in...
Prevention of relapse is a major challenge in schizophrenia, a disease characterized by poor adherence to antipsychotic medication leading to multiple rehospitalizations and a substantial burden-of-care.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc. announced that the Phase III clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple...
Advaxis, Inc. announced that it is increasing its focus on neoantigen-directed immunotherapies and closing the AIM2CERV Phase III clinical trial...
The Mental Health Foundation, a leading UK charity, launches Mental Health Awareness Week from 8-14May.